Rezdiffra (Resmetirom) Access Update: What Providers and Prescribers Need to Know in 2026

Two years since its March 2024 FDA accelerated approval, resmetirom (Rezdiffra) remains the first and only liver-directed pharmacotherapy for noncirrhotic MASH with moderate to advanced fibrosis approved under its specific mechanism of action. In 2026, providers are navigating a maturing but still complex prescribing landscape — one shaped by evolving insurance formularies, a second FDA-approved MASH therapy, and patients who are increasingly aware of their treatment options.

This guide is written for hepatologists, gastroenterologists, endocrinologists, and PCPs who are prescribing or considering Rezdiffra and want a practical update on the access environment.

Current Indication and Patient Selection

Rezdiffra is FDA-approved in conjunction with diet and exercise for adults with noncirrhotic NASH (MASH) with moderate to advanced liver fibrosis (F2–F3). The drug is contraindicated in patients with decompensated cirrhosis. It is not yet established in compensated cirrhosis (F4), though an open-label cohort is enrolled in the ongoing MAESTRO-NASH trial.

Dosing is weight-based: 80 mg once daily for patients weighing less than 100 kg; 100 mg once daily for patients weighing 100 kg or more. Reduce to 60 mg or 80 mg respectively when co-administered with moderate CYP2C8 inhibitors (e.g., clopidogrel). Avoid concomitant use with strong CYP2C8 inhibitors such as gemfibrozil.

Key patient selection criteria for insurance approval: Most payers require a liver biopsy confirming NASH with fibrosis stage F2 or F3, along with documentation of concurrent diet and exercise counseling. Some plans require evidence of NAFLD Activity Score (NAS) ≥ 4. Confirm your specific payer's requirements before initiating the PA.

Supply Status: No Active Shortage

As of 2026, resmetirom is not listed on the FDA drug shortage database. Madrigal Pharmaceuticals has maintained supply continuity since the April 2024 commercial launch. The access difficulties providers encounter are structural — specialty pharmacy distribution, formulary placement, and prior authorization workflows — not supply-related.

Prior Authorization: What Works in 2026

Prior authorization remains the single biggest access barrier for patients in 2026. Based on clinical experience and expert recommendations, here are the key elements of a strong PA submission:

Biopsy documentation: Pathology report confirming NASH with fibrosis stage F2 or F3 (and NAS ≥ 4 if required by payer)

Noninvasive test data: MRI-PDFF, FIB-4, liver stiffness measurement (LSM) to support biopsy staging if available

Diet and exercise counseling: Documentation that the patient is on (or enrolled in) an appropriate lifestyle program, as the drug is indicated in conjunction with these changes

Prescriber NPI and specialty: Include hepatology or gastroenterology specialty information to reduce payer push-back

Letter of medical necessity: Prepare this proactively for patients at high risk of initial denial (e.g., Medicaid, Medicare with complex plan designs)

When PAs are denied, peer-to-peer review with the medical director is often effective, particularly when you can articulate the severity of the patient's fibrosis and the absence of effective alternatives prior to Rezdiffra's approval.

Specialty Pharmacy Workflow

Rezdiffra is distributed exclusively through specialty pharmacies as a Limited Distribution Drug (LDD). Madrigal Patient Support serves as the hub for specialty pharmacy routing. Your office should:

Send the prescription to Madrigal Patient Support (877-219-7770) or use electronic prescribing to the designated specialty pharmacy

Ensure your staff is familiar with the enrollment form and required clinical documents

Advise patients to expect mail delivery — Rezdiffra cannot be picked up at retail pharmacies

Ask patients about insurance tier and provide the copay card information to commercially insured patients before they leave the appointment

Monitoring Patients on Rezdiffra

Per the prescribing information and expert panel recommendations, consider the following monitoring parameters for patients on resmetirom:

Liver enzymes (ALT/AST): Monitor for hepatotoxicity. Discontinue if liver injury is suspected.

Gallbladder symptoms: Cholelithiasis and cholecystitis occur at slightly higher rates in treated patients. Interrupt treatment if acute gallbladder event is suspected.

Statin co-prescribing: Limit rosuvastatin and simvastatin to 20 mg/day; limit pravastatin and atorvastatin to 40 mg/day due to transporter-mediated interactions.

Noninvasive efficacy monitoring: MRI-PDFF at 12–24 weeks. A ≥30% relative reduction in MRI-PDFF is associated with more than 5-fold greater odds of histologic response — this serves as a useful early efficacy marker.

The Evolving Treatment Landscape: Resmetirom and Semaglutide

The August 2025 FDA approval of semaglutide (Wegovy, 2.4 mg weekly) for MASH adds both an option and a decision point. Clinical data from the MAESTRO-NASH trial shows that resmetirom efficacy is maintained regardless of background GLP-1 RA or SGLT2i use, suggesting complementary rather than competing mechanisms. For patients already on GLP-1 therapies for T2D, adding resmetirom may be clinically appropriate when fibrosis warrants it.

When selecting between the two approved MASH therapies, consider: patient weight and metabolic comorbidities (semaglutide favored if obesity/T2D are primary concerns), route of administration preference (oral daily vs. weekly injection), insurance formulary placement, and tolerability of GI side effects common to both.

How medfinder Supports Your Patients

When your patients are struggling to navigate the specialty pharmacy system, medfinder for providers can help. medfinder calls pharmacies on behalf of patients to find which ones can fill their prescription, reducing the administrative burden on your staff and helping patients get answers faster. Learn more in our provider guide: How to Help Your Patients Find Rezdiffra in Stock.